Skip to main content
Lilly, AstraZeneca end trials of Alzheimer's drug

Eli Lilly and Co. and AstraZeneca are the latest companies to abandon Alzheimer's drug trials. The companies decided to end late-stage trials for lanabecestat, a beta secretase cleaving enzyme inhibitor, after an independent data monitoring committee determined the trials were unlikely to meet their primary goals.

Full Story: